Back to Market Feed

Product Information

BEVESPI AEROSPHERE INHALER is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $40.8578 per GM under NDC 00310460012. Its NADAC has been published 492 times since Mar 22, 2017.

FDA first approved this application on Apr 25, 2016.

BEVESPI AEROSPHERE INHALER

Glycopyrrolate and formoterol fumarate
$40.8578per GM

Strength

4.8; 9 ug/1; ug/1

NDC

00310460012

Classification

Brand

Dosage Form

AEROSOL, METERED

Route

RESPIRATORY (INHALATION)

Effective Date

8/19/2026

Approval Type

New Drug (NDA)

FDA Application

NDA208294

FDA Approved

4/25/2016

On Market Since

10/3/2016

Pharmacological Classes

Adrenergic beta2-Agonists
Anticholinergic
Cholinergic Antagonists
Cholinergic Muscarinic Antagonist
Cholinergic Muscarinic Antagonists
beta2-Adrenergic Agonist

Price Statistics

The NADAC for BEVESPI AEROSPHERE INHALER has been published 492 times since Mar 22, 2017, and over the history we have for it it has risen 36.0%. The table below summarizes its recorded NADAC range and movement.

Current price$40.8578 per GM
All-time high$40.9856 (May 13, 2026)
All-time low$30.0343 (Mar 22, 2017)
52-week high$40.9856
52-week low$39.7794
Median price$35.4750
Average price$35.6589
Largest weekly change+6.0% (Jan 10, 2018)
Weeks tracked492
Tracking sinceMar 22, 2017

Price History

1W

-0.0%

1M

-0.0%

3M

-0.0%

6M

-0.3%

1Y

+2.7%

3Y

+8.6%

5Y

+15.2%

All

+36.0%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Glycopyrrolate and formoterol fumarate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

CUVPOSA 1 MG/5 ML SOLUTION
Brand
00259050116•Merz Pharmaceuticals, LLC
$1.0080
per ML
VESICARE LS 5 MG/5 ML SUSP
Brand
51248025099•Astellas Pharma US, Inc.
$1.6383
per ML
ADVAIR 100-50 DISKUS
Brand
00173069500•GlaxoSmithKline LLC
$2.4861
per EA
VENTOLIN HFA 90 MCG INHALER
Brand
00173068224•GlaxoSmithKline LLC
$2.7195
per GM
OXYTROL FOR WOMEN 3.9 MG/24HR
Brand
00023963704•Allergan, Inc.
$2.7497
per EA
OXYTROL FOR WOMEN 3.9 MG/24HR
Brand
00023963708•Allergan, Inc.
$2.7497
per EA
LOMOTIL 2.5-0.025 MG TABLET
Brand
00025006131•Pfizer Inc.
$3.0028
per EA
VENTOLIN HFA 90 MCG INHALER
Brand
00173068220•GlaxoSmithKline LLC
$3.0351
per GM
ADVAIR 250-50 DISKUS
Brand
00173069604•GlaxoSmithKline LLC
$3.1083
per EA
ADVAIR 250-50 DISKUS
Brand
00173069600•GlaxoSmithKline LLC
$3.1226
per EA

Frequently asked questions

What is the NADAC price of BEVESPI AEROSPHERE INHALER?

The current National Average Drug Acquisition Cost (NADAC) for BEVESPI AEROSPHERE INHALER, manufactured by AstraZeneca Pharmaceuticals LP, is $40.8578 per GM (NDC 00310460012), effective Aug 19, 2026.

How has the price of BEVESPI AEROSPHERE INHALER changed over time?

Over the history we have for it, the NADAC for BEVESPI AEROSPHERE INHALER has risen 36.0%. It has been tracked across 492 weekly CMS publications since Mar 22, 2017.

What are the highest and lowest recorded NADAC prices for BEVESPI AEROSPHERE INHALER?

Since Mar 22, 2017, the NADAC for BEVESPI AEROSPHERE INHALER has ranged from a low of $30.0343 (Mar 22, 2017) to a high of $40.9856 (May 13, 2026), with a median of $35.4750 per GM.

Are there cheaper alternatives to BEVESPI AEROSPHERE INHALER?

No other NADAC-published product currently shares the active ingredient and strength of BEVESPI AEROSPHERE INHALER in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures BEVESPI AEROSPHERE INHALER?

BEVESPI AEROSPHERE INHALER (NDC 00310460012) is labeled by AstraZeneca Pharmaceuticals LP, and CMS classifies it as a brand product.